Blue Earth Diagnostics is highlighting results from a clinical study that has investigated the efficacy of the PET imaging agent F-18 rhPSMA-7.3 for detecting recurrent prostate cancer.
Results from the phase III SPOTLIGHT trial were reported at the American Urological Association's 2023 annual meeting in Chicago by presenter Dr. Brian Helfand of NorthShore University HealthSystem in Evanston, IL. The research included 76 men and showed high prostate cancer detection rates by F-18 rhPSMA-7.3 across all regions. It also found that 43% of the men had distant extra-pelvic recurrences, Blue Earth said.
